COMMUNIQUÉS West-GlobeNewswire

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
MediciNova to Participate in Two Investor Conferences in September
08/09/2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
08/09/2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
08/09/2026
Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical Officer Expanded leadership team brings decades of [...]
Transactions in connection with share buy-back program
08/09/2026
Company announcement no. 34 - 26 08 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Du massage intelligent au bien-être proactif : SKG élargit sa gamme de dispositifs de santé portables à l’occasion de l’IFA 2026
08/09/2026
La présentation à Berlin associe la technologie de massage portable de SKG à la récupération, à l’accompagnement de l’entraînement et au suivi préventif de la santé BERLIN, 08 sept. 2026 (GLOBE NEWSWIRE) -- SKG Health [...]
From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026
08/09/2026
Berlin showcase connects SKG's portable massage technology with recovery, training support and proactive health monitoring BERLIN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SKG Health is showcasing an expanded portfolio of [...]
New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
08/09/2026
Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple cancer types and [...]
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
08/09/2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled [...]
First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia
08/09/2026
New veterinary treatment targets insulin dysregulation, the most common cause of laminitis in horses and ponies Bracknell, United Kingdom – Boehringer Ingelheim has announced the availability in Great Britain of the [...]
PannTheraPi Receives ANSM Approval to Advance PTI5803 into Phase 2a in Focal Cortical Dysplasia
08/09/2026
Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy Nîmes, France, 8 September 2026 — PannTheraPi , a clinical- [...]
PannTheraPi obtient l'approbation de l’ANSM pour l’entrée en Phase 2a de PTI5803 dans la dysplasie corticale focale
08/09/2026
L’étude de Phase 2a évaluera PTI5803, un traitement first-in-class ciblant le canal Pannexin1, chez des patients atteints de dysplasie corticale focale pharmacorésistante, une forme rare et sévère d’épilepsie Nîmes, le [...]
Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
08/09/2026
Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadership team as the Company [...]
Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
08/09/2026
Pa -positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatment Only one exacerbation meeting the Hill/EMBARC criteria was [...]
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
08/09/2026
Single ascending dose (SAD) portion completed in healthy volunteers, with dose-proportional pharmacokinetics (PK), clear evidence of ERAP1 target engagement, and no safety or tolerability concerns observed GRWD0715 [...]
Rapid Nutrition Reports 227.5% H1 Revenue Growth as Group Enters Transformational Second Half
08/09/2026
Completion of the HealthShop+ acquisition shortly before period-end establishes a materially enlarged operating and revenue base for H2 and beyond LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext [...]
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
08/09/2026
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence [...]

Pages